PeptideHormone

Pasireotide

A broader-spectrum somatostatin analog hitting more receptor subtypes.

AnalogEstablishedBased on SomatostatinCompare lineage

Identity

Class
Somatostatin analog (cyclic hexapeptide)
Source
Synthetic analog of somatostatin
Receptor
Somatostatin receptors (SSTR1, 2, 3, and 5)

Key properties

Molecular weight
~1,047.2 Da
Half-life (native)
~12 h
Model dosing

Approximate values for the native hormone. Engineered analogs are often deliberately larger and far longer-acting.

Mechanism

Pasireotide binds a wider range of somatostatin receptor subtypes than octreotide — including SSTR1, 2, 3, and 5 — giving it a different activity profile, notably more SSTR5 engagement that underlies its use in conditions octreotide addresses less well.

Reference notes

  • Its broader SSTR-subtype coverage is the key distinction from octreotide and lanreotide.
  • Greater SSTR5 affinity drives a different clinical profile.
  • Illustrates how analog receptor-selectivity engineering changes effects.

Selected literature

Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.

  1. 1.Diagnosis and Treatment of Pituitary Adenomas: A Review · JAMA, 2017 · PMID 28170483
  2. 2.Acromegaly · Nature reviews. Disease primers, 2019 · PMID 30899019